Download PDF

1. Company Snapshot

1.a. Company Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States.The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder.It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.


Bionomics Limited has a licensing agreement with Merck & Co., Inc.The company was incorporated in 1996 and is based in Eastwood, Australia.

Show Full description

1.b. Last Insights on BNOX

Bionomics Limited's recent performance was negatively driven by the uncertainty surrounding its proposed re-domiciliation from Australia to the United States. The company's Supreme Court approval on December 16, 2024, may have alleviated some concerns, but the complex nature of the re-domiciliation process and potential regulatory hurdles likely contributed to market volatility.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation

Dec -16

Source: globenewswire.com

Card image cap

Results of Scheme Meeting

Dec -12

Source: globenewswire.com

Card image cap

Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting

Dec -03

Source: globenewswire.com

Card image cap

Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States

Dec -02

Source: globenewswire.com

Card image cap

Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement

Nov -08

Source: globenewswire.com

Card image cap

Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program

Nov -04

Source: globenewswire.com

Card image cap

Bionomics to Present at the ThinkEquity Conference

Oct -23

Source: globenewswire.com

Card image cap

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct -14

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (0.00%)

6. Segments

Drug Development

Expected Growth: 10.2%

Growing prevalence of anxiety disorders and depression, increasing demand for novel cancer treatments, and Bionomics' proprietary ionX technology driving innovation in target identification and validation.

7. Detailed Products

Genomic Analysis

Bionomics Limited offers genomic analysis services to help researchers and clinicians understand the genetic basis of diseases and develop personalized treatments.

Transcriptomics Analysis

The company provides transcriptomics analysis services to study gene expression and identify biomarkers for disease diagnosis and treatment.

Proteomics Analysis

Bionomics Limited offers proteomics analysis services to study protein structure and function, and identify potential therapeutic targets.

Metabolomics Analysis

The company provides metabolomics analysis services to study metabolic pathways and identify biomarkers for disease diagnosis and treatment.

Bioinformatics Services

Bionomics Limited offers bioinformatics services to analyze and interpret large-scale biological data, including genomics, transcriptomics, and proteomics data.

Data Analytics and Visualization

The company provides data analytics and visualization services to help researchers and clinicians interpret and visualize complex biological data.

8. Bionomics Limited's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Bionomics Limited is moderate due to the availability of alternative products in the market.

Bargaining Power Of Customers

The bargaining power of customers is high due to the presence of a large number of customers who can easily switch to alternative products.

Bargaining Power Of Suppliers

The bargaining power of suppliers is low due to the presence of multiple suppliers in the market, giving Bionomics Limited the power to negotiate prices.

Threat Of New Entrants

The threat of new entrants is moderate due to the presence of barriers to entry, such as high capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the market, leading to a competitive landscape.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 2.11%
Debt Cost 3.95%
Equity Weight 97.89%
Equity Cost 3.53%
WACC 3.54%
Leverage 2.16%

11. Quality Control: Bionomics Limited passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
CytomX Therapeutics

A-Score: 5.3/10

Value: 5.7

Growth: 6.2

Quality: 9.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Harmony Biosciences

A-Score: 5.2/10

Value: 7.0

Growth: 9.4

Quality: 9.0

Yield: 0.0

Momentum: 1.5

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
iTeos Therapeutics

A-Score: 4.6/10

Value: 7.8

Growth: 3.6

Quality: 6.2

Yield: 0.0

Momentum: 6.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
YS Biopharma

A-Score: 4.5/10

Value: 8.8

Growth: 4.6

Quality: 5.9

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Amylyx Pharmaceuticals

A-Score: 4.3/10

Value: 8.2

Growth: 3.6

Quality: 7.2

Yield: 0.0

Momentum: 5.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Bionomics

A-Score: 3.6/10

Value: 3.9

Growth: 3.9

Quality: 8.2

Yield: 0.0

Momentum: 4.5

Volatility: 1.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.25$

Current Price

0.25$

Potential

-0.00%

Expected Cash-Flows